Volume 9 , Issue 2 , June 2021 , Pages: 106 - 110
Expression of HER2 in Gastric Carcinoma According to Tumor Location
Monoar Hossain, Department of Surgery, Khulna Medical College, Khulna, Bangladesh
Miranur Rahman, National Institute of Cancer Research & Hospital (NICRH), Dhaka, Bangladesh
Mohammad Sahajadul Alam, Department of Surgical Oncology, National Institute of Cancer Research & Hospital (NICRH), Dhaka, Bangladesh
Monzurul Islam, Department of Surgical Oncology, National Institute of Cancer Research & Hospital (NICRH), Dhaka, Bangladesh
Received: Apr. 22, 2021;       Accepted: May 31, 2021;       Published: Jun. 7, 2021
DOI: 10.11648/j.crj.20210902.14        View        Downloads  
Introduction: HER2/neu (c-erbB-2) is an oncogene that encodes a transmembrane glycoprotein with tyrosine kinase activity known as 185 kDa. This 185 kDa belongs to the epidermal growth factor receptor. Though HER-2 expression has been extensively found in advanced gastric cancer, few recent studies have evaluated the same in early gastric cancers. HER-2 overexpression is considered one of the poorest prognostic variables after nodal status in early gastric cancers too. Aim of the study: To find out the expression of HER2 in gastric carcinoma according to tumor location. Material & Methods: This cross-sectional study was conducted in the Department of Surgical Oncology of National Institute of Cancer, Research and Hospital, Mohakhali, Dhaka. The study period was from March 2014 to April 2015. A total of 80 patients were included in the study. After receiving the gastrectomy specimen, it was fixed in 10% formaldehyde. Statistical analysis was carried out using a computer-based software package for social science (SPSS 16.1). Ethical clearance was taken from the ethical committee of NICRH. Results: The highest patients were from the 61-70 years age group and the lowest were from 71-80 years. The mean age of the patients was 59.71 (±10.19) years. The female to male ratio in this study was 1: 2.48. The leading number of patients presented with abdominal pain where the vague abdominal discomfort was also included. They were 75%. This clinical condition was followed by vomiting which coined 58.75% of respondents. Out of 80 patients, 27 (33.75%) patients bore A +ve blood group whereas 23 (28.75%) patients had B+ve blood group. Most of the tumors were located in the distal (Noncardiac) part of the stomach (75%). Regarding staging 79 (98.75%) patients were in the advanced stage of the disease. Most of the tumors were located in the distal part of the stomach (11.67%). Conclusion: We reported a 12.5% of positive HER2 expression (IHC=3+ & 2+) in a series of 80 surgical specimens of gastric cancer patients. We also observed that positive HER2 expression varied depending on the histology and the primary tumor localization.
Expression, HER2/neu, Gastric Carcinoma, Tumor, Growth Factor
To cite this article
Monoar Hossain, Miranur Rahman, Mohammad Sahajadul Alam, Monzurul Islam, Expression of HER2 in Gastric Carcinoma According to Tumor Location, Cancer Research Journal. Vol. 9, No. 2, 2021, pp. 106-110. doi: 10.11648/j.crj.20210902.14
Copyright © 2021 Authors retain the copyright of this article.
This article is an open access article distributed under the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/) which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
[ 1 ]
Yonemura Y, Ninomiya I, Yamaguchi A, Fushida S, Kimura H, Ohoyama S. Miyazaki l, Endou Y, Tanaka M, Sasaki T. Evaluation of immunoreactivity for erbB-2 protein as a marker of poor short term prognosis in gastric cancer Cancer Fes. 1991; 51: 1034-8.
[ 2 ]
Gravalos C, Jimeno A. HER2 in gastric cancer: a new prognostic factor and a novel therapeutic target. Annals of oncology. 2008 Sep 1; 19 (9): 1523-9.
[ 3 ]
Montgomery E, Goldblum JR, Greenson JK, Haber MM, Lamps LW, Lauwers GY, Lazenby AJ, Lewin DN, Robert ME, Washington K, Zahurak ML. Dysplasia as a predictive marker for invasive carcinoma in Barrett esophagus: a follow-up study based on 138 cases from a diagnostic variability study. Human pathology. 2001 Apr 1; 32 (4): 379-88.
[ 4 ]
Correa P. Helicobacter pylori and gastric cancer: state of the art. Cancer Epidemiology and Prevention Biomarkers. 1996 Jun 1; 5 (6): 477-81.
[ 5 ]
Sastre J, García-Saenz JA, Díaz-Rubio E. Chemotherapy for gastric cancer. World journal of gastroenterology: WJG. 2006 Jan 14; 12 (2): 204.
[ 6 ]
Tanner M, Hollmen M, Junttila TT, Kapanen AI, Tommola S, Soini Y, Helin H, Salo J, Joensuu H, Sihvo E, Elenius K. Amplification of HER-2 in gastric carcinoma: association with Topoisomerase IIα gene amplification, intestinal type, poor prognosis and sensitivity to trastuzumab. Annals of Oncology. 2005 Feb. 1; 16 (2): 273-8.
[ 7 ]
Sakai K, Mori S, Kawamoto T, Taniguchi S, Kobori O, Morioka Y, Kuroki T, Kano K. Expression of epidermal growth factor receptors on normal human gastric epithelia and gastric carcinomas. Journal of the National Cancer Institute. 1986 Nov 1; 77 (5): 1047-52.
[ 8 ]
Kramer BS, Johnson KA. Other gastrointestinal cancers: stomach, liver. Cancer prevention and control. New York: Marcel Dekker. 1995: 673-94.
[ 9 ]
Ishida T, Tsujisaki M, Hanzawa Y, Hirakawa T, Hinoda Y, Imai K, Yachi A. Significance of erb B-2 Gene Product as a Target Molecule for Cancer Therapy. Scandinavian journal of immunology. 1994 May; 39 (5): 459-66.
[ 10 ]
Park WS, Oh RR, Park JY, Lee SH, Shin MS, Kim YS, Kim SY, Lee HK, Kim PJ, Oh ST, Yoo NJ. Frequent somatic mutations of the β-catenin gene in intestinal-type gastric cancer. Cancer research. 1999 Sep 1; 59 (17): 4257-60.
[ 11 ]
Yano, T., Doi, T., Ohtsu, A., Boku, N., Hashizume, K., Nakanishi, M., & Ochiai, A. (2006). Comparison of HER2 gene amplification assessed by fluorescence in situ hybridization and HER2 protein expression assessed by immunohistochemistry in gastric cancer. Oncology reports, 15 (1), 65–71.
[ 12 ]
Bang, Y. J., Van Cutsem, E., Feyereislova, A., Chung, H. C., Shen, L., Sawaki, A., Lordick, F., Ohtsu, A., Omuro, Y., Satoh, T., Aprile, G., Kulikov, E., Hill, J., Lehle, M., Rüschoff, J., Kang, Y. K., & ToGA Trial Investigators (2010). Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet (London, England), 376 (9742), 687–697. https://doi.org/10.1016/S0140-6736(10)61121-X
[ 13 ]
Kang Y, Bang Y, Lordick F, Park S, Sawaki A, Chung H, Shen L, Xu JM, Leon-Chong J, Van Cutsem E. Incidence of gastric and gastro-esophageal cancer in the ToGA trial: correlation with HER2 positivity. InGastrointestinal Cancers Symposium 2008 (Vol. 75).
[ 14 ]
Mizutani T, Onda M, Tokunaga A, Yamanaka N, Sugisaki Y. Relationship of C-erbB-2 protein expression and gene amplification to invasion and metastasis in human gastric cancer. Cancer. 1993 Oct 1; 72 (7): 2083-8.
Browse journals by subject